Results 201 to 210 of about 51,089 (251)

Cardiac myosin inhibitors in hypertrophic cardiomyopathy: gaps in knowledge and future opportunities

Shanghai Chest
Mehran Rahimi, Monica Ahluwalia, Ralf Martz Sulague, Jacques Kpodonu   +3 more
openaire   +1 more source

Myosin Modulator Aficamten Inhibits Force by Altering Myosin's Biochemical Activity Without Changing Thick Filament Structure. [PDF]

JACC Basic Transl Sci
Mohran S, Kooiker KB, Naim A, Pilagov M, Asencio A, Turner KL, Ma W, Flint G, Jiang S, Zhao J, McMillen TS, Mandrycky C, Mahoney-Schaefer M, Irving TC, Tanner BCW, Kad NM, Regnier M, Moussavi-Harami F.   +17 more
europepmc   +1 more source

Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin. [PDF]

JACC Case Rep
Alabdaljabar MS, Desai M, Geske JB.
europepmc   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Comparing cryo-EM structures of the vertebrate cardiac muscle thick filament. [PDF]

Biophys Rev
Craig R, Dutta D, Koubassova NA, Tsaturyan AK, Padrón R.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

First-in-class cardiac myosin inhibitor reduces symptoms of HCM

Nature Reviews Cardiology, 2020
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire   +4 more sources

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
openaire   +3 more sources